Label Changes for:

Xopenex (levalbuterol HCl) Inhalation Solution Concentrate, 1.25 mg/0.5 mL

September 2012

Changes have been made to the ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – September 2012

 

ADVERSE REACTIONS

Postmarketing Adverse Reactions
  • metabolic acidosis.....added
     
Hide
(web2)